21:37 , Dec 16, 2016 |  BC Week In Review  |  Clinical News

PyL: Ph II/III OSPREY started

Progenics began the open-label, North American Phase II/III OSPREY trial to evaluate a single dose of IV PyL in about 300 patients with high-risk prostate cancer with recurrence or metastatic disease. Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), New...